of chronic kidney disease. Novel therapeutic strategies to

including dual therapy with an angiotensin-converting

enzyme inhibitor and an angiotensin-receptor blocker, have

been suggested to achieve more complete disruption of the

target of angiotensin II, in the progression of chronic

kidney disease has become a subject of significant interest

over the past decade. Experimental studies in animals have

shown that persistently elevated aldosterone levels lead to

pathohistological changes in the kidney, along with renal

and cardiac fibrosis. Incomplete suppression of aldosterone

may, therefore, contribute to the deleterious effects of the

disease. Clinical trials in adults have shown a potential role

for mineralocorticoid receptor blockers to delay further the

development of end-stage renal disease by completing

receptor blockade produces a significant anti-proteinuric

effect and has minimal risk of causing hyperkalemia if the

condition of the patients is closely monitored. Further

studies will need to be conducted to determine whether

mineralocorticoid receptor blockers are equally effective

and safe for the treatment of chronic kidney disease in

children.